Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57736
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWorawut Choeypraserten_US
dc.contributor.authorThitinun Yansomdeten_US
dc.contributor.authorRungrote Natesirinilkulen_US
dc.contributor.authorKarn Wejaphikulen_US
dc.contributor.authorPimlak Charoenkwanen_US
dc.date.accessioned2018-09-05T03:48:56Z-
dc.date.available2018-09-05T03:48:56Z-
dc.date.issued2017-03-01en_US
dc.identifier.issn1442200Xen_US
dc.identifier.issn13288067en_US
dc.identifier.other2-s2.0-85005810433en_US
dc.identifier.other10.1111/ped.13136en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85005810433&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/57736-
dc.description.abstract© 2016 Japan Pediatric Society Background: Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor and is approved for indefinite treatment of pediatric chronic myelogenous leukemia (CML). Potential side-effects regarding growth failure and bone metabolism have been reported but data are still scarce in pediatric CML. Methods: Six chronic-phase CML children on IM treatment with a median age of 9.87 years (range, 5.33–12.67 years) were enrolled in the study. Growth, bone mineral density (BMD), bone parameters, 25(OH)-vitamin D3 (25-OHD3) and blood tests including parathyroid hormone, insulin-like growth factor-1 (IGF-1), IGF binding protein 3, thyroid function test and sex hormones were assessed. Results: Median duration of IM treatment was 78.5 months. Height velocity was suppressed during the first 30 months of treatment and improved gradually afterwards. Two patients (33.3%) had decreased lumbar spine BMD z-scores (<1.5 SD). Patients with decreased BMD had higher mean IM exposure time than those with normal BMD. The majority of patients (n = 5) had low 25-OHD3 (<30 ng/mL), but there was no correlation between BMD and 25-OHD3 status. Other blood tests were normal. Conclusions: This study supports and confirms the need for monitoring the side-effects of IM treatment on growth, bone density and vitamin D status in pediatric CML. Prolonged IM treatment was associated with low BMD without disturbing bone parameters. There was high prevalence of vitamin D insufficiency. Therefore, the beneficial effect of vitamin D supplement should be explored with regard to the effects on height velocity and BMD in CML patients with vitamin D insufficiency.en_US
dc.subjectMedicineen_US
dc.titleAdverse effects of imatinib in children with chronic myelogenous leukemiaen_US
dc.typeJournalen_US
article.title.sourcetitlePediatrics Internationalen_US
article.volume59en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.